In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide. If you cannot link drug treatment and diagnosis, please provide the number of patients by drug regardless of the disease diagnosis.

 

Aubagio (teriflunomide)

Avonex (interferon beta-1a)

Betaferon (interferon beta-1b)

Copaxone (glatiramer acetate)

Glatiramer acetate generic [eg Brabio]

Extavia (beta interferon-1b)

Gilenya (fingolimod)

Lemtrada (alemtuzumab)

Rebif (beta interferon-1a)

Tecfidera (dimethyl fumarate)

Tysabri (natalizumab)

Ampyra (Fampyra)

Peginterferon beta-1a (Plegridy)

Daclizumab (Zinbryta)

Cladribine (Mavenclad)

Others

 

The information requested above has been repeatedly asked for over the past two years, with requests recurring every 4 months.

 

The most recent request 4116 2017 is published here:

https://www.royalsurrey.nhs.uk/wp-content/uploads/2018/02/fFOI-4504-MS-Drugs.pdf.

 

These requests have been considered and have been deemed vexatious under Section 14(1) for the Freedom of Information Act 2000. For this reason, we will not be providing the requested information.

The Information Commissioner recognises that dealing with unreasonable requests can place a strain on resources and get in the way of delivering mainstream services or answering legitimate requests. Section 14 (1) is designed to protect public authorities by allowing them to refuse any requests which have the potential to cause disproportionate or unjustified level of disruption, irritation or distress.

A request which would not normally be regarded as vexatious in isolation may assume that quality once considered in context. Submitting frequent repeat requests that have been answered and published previously places a strain on the Trust resources, and these requests are contributing to that aggregated burden.

©2019 Royal Surrey County Hospital

Log in with your credentials

Forgot your details?